Research of Gene therapy for patients with head and neck carcinomas using CyclinD1

CyclinD1对头颈癌患者的基因治疗研究

• 批准号: 09671772
• 负责人: KUMAZAWA Hirobumi
• 金额: $ 1.92万
• 依托单位: Kansai Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1999
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09671772/
• 关键词: Head and neck caricinomas; Gene therapy; Cyclin D1; サイクリンD1; 頭頚部扁平上皮癌; 細胞周期; サイクリン; 予後因子; 頭頸部扁平上皮癌; 遺伝子増幅; トランスフェクション

The grading of biological malignancy was studied in patients with head and neck squamous cell carcinomas. The studies concerning the amplification of the cyclinD1 gene and overexpression of cyclinD1 protein in head and neck squamous cell carcinomas were studied to evaluate the prognostic significance of patients. The amplification of cyclinD1 gene and overexpression of cyclinD1 protein in head and neck squamous cell carcinomas were considered to be useful for assessment of biological malignancy and prognosis in head and neck squamous cell carcinomas. These results suggest the approach for genetherapy using cyclinD1 for patients with head and neck carcinomas.

研究了头颈部鳞状细胞癌患者的生物学恶性程度。本研究通过对头颈部鳞癌中cyclinD1基因扩增和cyclinD1蛋白过表达的研究，探讨cyclinD1基因扩增和cyclinD1蛋白过表达与头颈部鳞癌患者预后的关系。cyclinD1基因的扩增和cyclinD1蛋白的过表达可作为判断头颈部鳞癌生物学恶性程度和预后的参考指标。这些结果为头颈部恶性肿瘤的基因治疗提供了新的思路。

项目成果

熊澤博文: "頭頚部癌治療の最前線-悪性度診断-" 癌の臨床. 44・11. 1183-1191 (1998)

Hirofumi Kumazawa：“头颈癌治疗的前沿 - 恶性肿瘤诊断”《癌症临床》44・11（1998）。

Ryoichi Kyomoto: "Cyclin D1-Gene amplification is amore important prognostic factor than its protein over-expression in human head and ueak carcium" Int.J.Cancer. 74・6. 576-581 (1997)

Ryoichi Kyomoto：“细胞周期蛋白 D1 基因扩增是比人类头部和 ueak 钙中蛋白质过度表达更重要的预后因素”Int.J.Cancer 74・6 (1997)。

R.Kyomoto, H.Kumazawa, Y.Toda, N.Sakaida, et al: "CYCLIN-D1-GENE ANPLIFICATION IS A MORE POTENT PROGNOSTIC FACTOR THAN ITS PROTEIN OVER-EXPRESSION IN HUMAN HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA" Int.J.Cancer. 74. 576-581 (1997)

R.Kyomoto、H.Kumazawa、Y.Toda、N.Sakaida 等人：“在人类头颈鳞状细胞癌中，CYCLIN-D1-基因扩增是比蛋白质过度表达更有效的预后因素”